Over 300 Colorado Auctions End Tomorrow 05/12 - Bid Now
Over 150 Total Lots Up For Auction at Two Locations - PA 05/15, NY 05/20

Dr. Nancy P. Mendenhall

Medical Director of UF Health Proton Therapy selected by University of Florida as 2018 Clinical Science Researcher of the Year
April 26, 2018
Rad Oncology Proton Therapy
Dr. Nancy P. Mendenhall
Jacksonville, Fla. (April 19, 2018) -- Nancy P. Mendenhall, M.D., has been named the 2018 Clinical Science Researcher of the Year by the University of Florida College of Medicine in Gainesville. The recognition comes, in part, for her recent research success in securing an $11.9 million grant for a national prostate cancer study comparing proton therapy to standard radiation treatment.

Each year, the college presents the award to a faculty member for outstanding achievement, productivity and research discovery. Mendenhall is a professor and associate chair of the UF department of radiation oncology. As the medical director of the UF Health Proton Therapy Institute in Jacksonville, she leads the clinical care and research program for the advanced form of radiation treatment – proton therapy. The Clinical Science Research Award is given for research having a close connection with clinical medicine that has a significant impact on the delivery of patient care.

Funded by the Patient-Centered Outcomes Research Institute, the prostate cancer study will enroll 3,000 patients at 42 treatment centers across the United States; half will be treated with standard radiation therapy and half will be treated with proton therapy. The study will collect information for five years on patient-reported quality of life, physician-reported and patient-reported side effects and prostate cancer recurrence. Some participants receiving proton therapy will have the option to be randomly assigned to receive eight weeks of treatment at a lower intensity or four weeks at a higher intensity, to determine which regimen has a greater impact on cure rates and side effects.
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats
Prostate cancer is the most common nonskin-cancer afflicting men in the United States, according to the American Cancer Society. It is estimated that 160,000 new cases of prostate cancer are diagnosed each year.

Since opening in 2006 under Mendenhall’s leadership, the UF Health Proton Therapy Institute has conducted dozens of clinical trials to treat more than 20 types of cancer. She and her team of clinical researchers have published over 150 articles in medical journals that report on the patient outcomes, treatment techniques and efficacy of proton therapy. She was instrumental in the development and launch of the first peer-reviewed medical journal dedicated to basic and clinical research in particle therapy – The International Journal of Particle Therapy. It is the official journal of the Particle Therapy Cooperative Group, an international organization for those interested in proton, light ion and heavy charged particle radiotherapy.


About UF Health Proton Therapy Institute
UF Health Proton Therapy Institute is a nonprofit 501(c)3 organization affiliated with the UF College of Medicine and the UF Health Cancer Center, a Florida Cancer Center of Excellence, dedicated to delivering state-of-the-art cancer treatment and setting new standards for treating and curing cancer. It is an accredited radiation oncology facility by the American College of Radiology. The cancer treatment facility houses both conventional radiation and proton therapy, and delivers proton therapy to 100 patients a day. For more information about the UF Health Proton Therapy Institute, please visit www.floridaproton.org, or call toll-free 877-426-9790.

You Must Be Logged In To Post A Comment

 

classifieds

Rad Oncology Homepage

RaySearch launches RayStation v2025 with expanded auto-planning
Adds support for treatment planning using the Leo Cancer Care upright patient positioning system
GE HealthCare adds AI-driven tools to radiation oncology portfolio
Plans to integrate software from Spectronic Medical into portfolio
P-Cure opens second Israel facility to scale compact proton therapy production
Will handle manufacturing and assembly of the company’s proprietary accelerator technology
Sun Nuclear acquires AI software firm Oncospace to bolster radiation oncology tools
Integrates predictive analytics and cloud-based planning solutions
Penn Medicine to add $224 million proton center, ramp up FLASH research
Will house two ProteusONE proton therapy systems from IBA in a 43,000-square-foot space
Will you be attending this year's National Proton Conference?
Q&A with Jennifer Maggiore, the National Association for Proton Therapy’s (NAPT) executive director
Varian and Embolx to jointly market embolization microcatheter in US
Expanding interventional oncology portfolio with a focus on liver-directed therapies
FDA clears Novartis’ Pluvicto for earlier use in PSMA-positive prostate cancer
Approved for patients who received one androgen receptor pathway inhibitor (ARPI) but not chemotherapy
World Theranostics Day: The dawn of precision cancer care
Insights from Dr. Ilya Gipp, oncology chief medical officer at GE HealthCare
Eckert & Ziegler to supply lu-177 to AtomVie under new global agreement
Increasingly used in targeted radiopharmaceutical therapies for various cancers